Indeed, several studies have shown that loss of PTEN expression is associated with liver and lymph node metastases, and correlates with a significant reduction in patients’ survival; however, the loss of nuclear PTEN is also a marker of poor clinical outcome [91,92]. The gene discussed is PTEN; the disease is metastatic malignant neoplasm in the lymph nodes.